Atle Fund Management AB
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 4, 2025), Atle Fund Management AB reported 38 stock positions worth $27.0 million. Its top holding was Eli Lilly (LLY) at 11.2% of the portfolio, followed by Abbvie (ABBV, 8.4%) and Neurocrine Biosciences (NBIX, 5.7%). Compared with Q2 2025, it opened 2 new positions, sold out of 1, added to 21 and reduced 8. The biggest buy was Krystal Biotech (KRYS, shares +109%) and the biggest sale Boston Scientific (BSX, shares −31%).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $27.0M (Q3 2025)
- SEC Filing
- 0001381843-25-000009 ↗ filed Nov 4, 2025
Holdings Value
Holdings 38 stocks · $27.0M
| LLY Eli Lilly & Co. | 11.19% | 37,244 | $3.0M | Reduce -3.8% |
| ABBV Abbvie Inc. | 8.39% | 92,105 | $2.3M | Add +6.0% |
| NBIX Neurocrine Biosciences Inc. | 5.67% | 102,625 | $1.5M | Add +16.1% |
| MRK Merck & Co. Inc. | 5.32% | 160,913 | $1.4M | Add +15.6% |
| TMO Thermo Fisher Scientific Inc. | 5.18% | 27,147 | $1.4M | Add +11.9% |
| ONC Beone Medicines Ltd.-ADR | 4.07% | 30,333 | $1.1M | Add +24.4% |
| BBIO Bridgebio Pharma Inc. | 3.57% | 174,722 | $963K | Add +5.6% |
| COR Cencora Inc. | 3.52% | 28,608 | $949K | Reduce -9.1% |
| ISRG Intuitive Surgical Inc. | 3.47% | 19,707 | $936K | Add +6.2% |
| GILD Gilead Sciences Inc. | 3.42% | 78,169 | $921K | Add +6.8% |
| BSX Boston Scientific Corp. | 3.33% | 86,680 | $898K | Reduce -31.3% |
| SYK Stryker Corp. | 3.31% | 22,769 | $894K | Reduce -17.1% |
| ALKS Alkermes PLC | 2.99% | 252,875 | $805K | Add +11.3% |
| KRYS Krystal Biotech Inc. | 2.93% | 42,191 | $791K | Add +109.3% |
| VRTX Vertex Pharmaceuticals Inc. | 2.74% | 17,766 | $739K | Reduce -27.0% |
| MIRM Mirum Pharmaceuticals Inc. | 2.70% | 93,605 | $729K | Reduce -12.4% |
| NAMS Newamsterdam Pharma Co. NV | 2.17% | 193,625 | $585K | Add +23.1% |
| IRTC Irhythm Holdings Inc. | 2.03% | 29,991 | $548K | Add +18.5% |
| EW Edwards Lifesciences Corp. | 2.01% | 65,659 | $542K | Add +14.5% |
| CAH Cardinal Health Inc. | 1.87% | 30,297 | $505K | Add +13.1% |
| UFPT Ufp Technologies Inc. | 1.81% | 22,986 | $487K | Add +5.0% |
| MRUS Merus NV | 1.78% | 47,999 | $480K | Reduce -19.9% |
| SLNO Soleno Therapeutics Inc. | 1.60% | 60,156 | $432K | Add +48.4% |
| RVMD Revolution Medicines Inc. | 1.57% | 85,355 | $423K | Add +3.7% |
| AMGN Amgen Inc. | 1.53% | 13,806 | $414K | Reduce -42.2% |
| DXCM Dexcom Inc. | 1.35% | 50,872 | $363K | No change |
| BCAX Bicara Therapeutics Inc. | 1.27% | 203,755 | $342K | Add +38.3% |
| IRON Disc Medicine Inc. | 1.19% | 45,690 | $321K | Add +85.3% |
| UNH Unitedhealth Group Inc. | 1.10% | 13,727 | $298K | No change |
| HRMY Harmony Biosciences Holdings | 1.00% | 92,074 | $269K | Add +6.7% |
| RNAM Avidity Biosciences Inc. | 0.89% | 51,978 | $240K | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.87% | 175,582 | $236K | No change |
| ACLX Arcellx Inc. | 0.83% | 25,732 | $224K | No change |
| SMMT Summit Therapeutics Inc. | 0.75% | 92,737 | $203K | No change |
| AUTL Autolus Therapeutics PLC | 0.75% | 1,169,634 | $202K | Add +5.8% |
| CELC Celcuity Inc. | 0.72% | 37,157 | $195K | New |
| MREO Mereo Biopharma Group PL-ADR | 0.62% | 764,901 | $167K | No change |
| JANX Janux Therapeutics Inc. | 0.48% | 49,820 | $129K | No change |
Portfolio Sells Q2 2025 → Q3 2025
| BSX Boston Scientific Corp. | Reduce -31.3% | 3.33% | −2.47 |
| VRNA Verona Pharma Ltd. | Sold out | 0.00% | −1.91 |
| VRTX Vertex Pharmaceuticals Inc. | Reduce -27.0% | 2.74% | −1.90 |
| LLY Eli Lilly & Co. | Reduce -3.8% | 11.19% | −1.73 |
| SYK Stryker Corp. | Reduce -17.1% | 3.31% | −1.34 |
| AMGN Amgen Inc. | Reduce -42.2% | 1.53% | −1.32 |
| COR Cencora Inc. | Reduce -9.1% | 3.52% | −0.52 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -12.4% | 2.70% | +0.37 |
| MRUS Merus NV | Reduce -19.9% | 1.78% | +0.43 |
Portfolio Buys Q2 2025 → Q3 2025
| KRYS Krystal Biotech Inc. | Add +109.3% | 2.93% | +1.75 |
| ONC Beone Medicines Ltd.-ADR | Add +24.4% | 4.07% | +1.54 |
| ABBV Abbvie Inc. | Add +6.0% | 8.39% | +1.49 |
| TMO Thermo Fisher Scientific Inc. | Add +11.9% | 5.18% | +0.97 |
| NAMS Newamsterdam Pharma Co. NV | Add +23.1% | 2.17% | +0.95 |
| NBIX Neurocrine Biosciences Inc. | Add +16.1% | 5.67% | +0.92 |
| RNAM Avidity Biosciences Inc. | New | 0.89% | +0.89 |
| CELC Celcuity Inc. | New | 0.72% | +0.72 |
| BCAX Bicara Therapeutics Inc. | Add +38.3% | 1.27% | +0.68 |
| IRON Disc Medicine Inc. | Add +85.3% | 1.19% | +0.63 |
| MRK Merck & Co. Inc. | Add +15.6% | 5.32% | +0.60 |
| BBIO Bridgebio Pharma Inc. | Add +5.6% | 3.57% | +0.51 |
| IRTC Irhythm Holdings Inc. | Add +18.5% | 2.03% | +0.36 |
| RVMD Revolution Medicines Inc. | Add +3.7% | 1.57% | +0.27 |
| ALKS Alkermes PLC | Add +11.3% | 2.99% | +0.20 |
| SLNO Soleno Therapeutics Inc. | Add +48.4% | 1.60% | +0.15 |
| EW Edwards Lifesciences Corp. | Add +14.5% | 2.01% | +0.09 |
| CAH Cardinal Health Inc. | Add +13.1% | 1.87% | −0.05 |
| GILD Gilead Sciences Inc. | Add +6.8% | 3.42% | −0.06 |
| HRMY Harmony Biosciences Holdings | Add +6.7% | 1.00% | −0.17 |
| AUTL Autolus Therapeutics PLC | Add +5.8% | 0.75% | −0.33 |
| UFPT Ufp Technologies Inc. | Add +5.0% | 1.81% | −0.48 |
| ISRG Intuitive Surgical Inc. | Add +6.2% | 3.47% | −0.85 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |